| Literature DB >> 24388103 |
M A Rahman1, A Salajegheh1, R A Smith1, A K-Y Lam2.
Abstract
BRAF is one of the most commonly mutated proto-oncogenes and plays a significant role in the development of numerous cancers of high clinical impact. Due to the commonality of BRAF mutations, a number of BRAF inhibitors have been developed as tools in the management of patients with cancers dependent on the action of mutant BRAF to drive cellular proliferation. In this review, we examine the current state of clinical trials and laboratory research concerning BRAF inhibitors in development and available for clinical use. We contrast the effectiveness of type-I and type-II BRAF inhibitors, the former typically showing much more restricted inhibitory selectivity and greater patient response rates.Entities:
Keywords: BRAF; Clinical trial; Kinase inhibitors; Multi-kinase inhibitor
Mesh：
Substances：
Year: 2013 PMID： 24388103 DOI： 10.1016/j.critrevonc.2013.12.008
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312